US13124Q1067 - ADR
CALLIDITAS THERAPEUTICS-ADR
NASDAQ:CALT (3/28/2024, 4:32:20 PM)
After market: 20.68 -0.33 (-1.57%)21.01
-0.48 (-2.22%)
Calliditas Therapeutics AB clinical-stage biopharmaceutical company. The company is headquartered in Stockholm, Stockholm and currently employs 174 full-time employees. The company went IPO on 2018-06-29. The company is focused on the development and commercialization of its product candidate Nefecon, a treatment for patients with inflammatory kidney disease (IgA nephropathy) who are at risk of progressing to renal failure. Nefecon is derived from the TARGIT technology, in which the capsule containing the active drug substance is coated in a way that the capsule remains intact as it passes through the stomach and intestine until it reaches the lower small intestine, where the release of content takes place. Nefeco combines time lag effect with a concentrated release of the active substance budesonide, within a designated target area.
CALLIDITAS THERAPEUTICS-ADR
D5, Kungsbron 1,
Stockholm STOCKHOLM 11122
P: 4684113005.0
CEO: Renee Aguiar-Lucander
Employees: 174
Website: https://www.calliditas.se/
/PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company")'s licensing partner Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm:...
/PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ('Calliditas') today announced that the FDA has granted an orphan drug...
/PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) and (Nasdaq Stockholm: CALTX) ("Calliditas"), a commercial biopharma company focused on rare diseases...
/PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the United States Patent and Trademark...
/PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (STO: CALTX) ("Calliditas"), a commercial biopharma company focused on rare diseases today provided a...
Here you can normally see the latest stock twits on CALT, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: